Drug approvals

Bethanechol Chloride Tablets
Lannett announced that it has received approval from the USFDA on its Abbreviated New Drug Application for Bethanechol Chloride Tablets in 5 mg, 10 mg, 25 mg, and 50 mg, the generic equivalent of Urecholine(R) Tablets marketed by Odyssey Pharma. Bethanechol Chloride is indicated for the treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention.
Bupropion Hydrochloride extended-release tablets

Actavis Group, the international generic pharmaceuticals company, today announced that it has received two separate approvals from the USFDA to market Bupropion Hydrochloride extended-release tablets (SR). Distribution of the products will commence immediately. Bupropion Hydrochloride extended-release tablets (SR), available in 150mg strength, are the generic equivalent of Wellbutrin SR(R) and are indicated for the treatment of major depressive disorder.

Pharma firms bet big on new B'desh law

The business standard reported an article by Joe C Mathew on Domestic drug firms, which lost the opportunity to sell cheap generic versions of patented medicines after changes in the Indian patent law three years ago, may find favorable market in Bangladesh. Chances of technical partnerships in Bangladesh have brightened after it changed its patent law in an attempt to become a hub for manufacturing cheap copies of patent-protected medicines. The World Trade Organisation allows such medicines to be produced in least developed countries till 2016. ( Link to full article business-standard.)